Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
IngevityFRA:IGX -2.38%62 EV-to-EBIT is 35.58 as of Aug. 15, 2026, which is 123% above its 10-year median of 15.99. GuruFocus rates FRA:IGX with a GF Score™ of 62/100 and a GF Value™ of €36.97. The stock has 7 warning signs investors should review. Among 1,250 Chemicals companies, Ingevity ranks worse than 74.48% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Ingevity's Enterprise Value for the quarter that ended in Jun. 2026 was €3,161.0 Mil.
Ingevity's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €92.1 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ingevity EV-to-EBIT Related Terms
Ingevity EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Ingevity's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Specialty Chemicals subindustry, Ingevity's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ingevity EV-to-EBIT vs Chemicals Industry
For the Chemicals industry and Basic Materials sector, Ingevity's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Ingevity's EV-to-EBIT falls into.
Ingevity's current Enterprise Value is €3,275.7 Mil.
Ingevity's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €92.1 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ingevity (FRA:IGX) has a EV-to-EBIT of 35.58 as of Aug. 15, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Ingevity and its competitors. This is 123% above median its historical median of 15.99. According to the industry distribution chart, Ingevity ranks #931 out of 1250 companies in the Chemicals industry, placing it in the top 74.5%.
Is Ingevity's EV-to-EBIT too high?
Ingevity's current EV-to-EBIT of 35.58 is 123% above median its 10-year median of 15.99. The Chemicals industry median EV-to-EBIT is 17.81. Ingevity's value of 35.58 is 99.8% above this industry median. Based on the distribution chart, Ingevity ranks #931 out of 1250 companies in the Chemicals industry, which is below the industry midpoint. Overall, Ingevity has a GF Score™ of 62/100, reflecting its overall financial health beyond just this single metric.
How does Ingevity's EV-to-EBIT compare to CC and KWR?
According to the Chemicals industry distribution chart, Ingevity ranks #931 out of 1250 companies for EV-to-EBIT. This places Ingevity in the lower half of its industry. The industry median EV-to-EBIT is 17.81. Ingevity's value of 35.58 is 99.8% above this benchmark. While the company's 10-year median is 15.99 vs. the industry median of 17.81, Ingevity has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Chemicals company?
The median EV-to-EBIT among Chemicals companies is 17.81, based on 1,250 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ingevity's current EV-to-EBIT of 35.58 is 99.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Ingevity and its competitors. For the Chemicals industry, the median EV-to-EBIT is 17.81 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ingevity's current EV-to-EBIT is 35.58, which is 123% above median its own 10-year median of 15.99. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ingevity stock overvalued right now?
Ingevity (FRA:IGX) has a current EV-to-EBIT of 35.58. The stock's GF Value™ is €36.97, compared to a current price of €61.50 — trading 66.4% above its estimated fair value. The current EV-to-EBIT is 35.58, which is 123% above median its 10-year median of 15.99 and 99.8% above the Chemicals industry median of 17.81. Ingevity's overall GF Score™ is 62/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Ingevity (FRA:IGX), the current EV-to-EBIT is 35.58 as of Aug. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ingevity (FRA:IGX) Overvalued in 2026?
Based on GuruFocus' analysis, Ingevity stock appears to be overvalued.
The current stock price of €61.50 is trading 66.4% above its estimated GF Value™ of €36.97.
Key valuation signals for FRA:IGX:
EV-to-EBIT: 35.58 (123% above median its 10-year median of 15.99)
GF Value™: €36.97 vs. price of €61.50 (66.4% above fair value)
Industry Position: 99.8% above the Chemicals median (#931 of 1250)
No single metric tells the full story. See the FRA:IGX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ingevity Corp is a chemical manufacturer based in the United States. It conducts its operations through three segments, namely Performance Chemicals, Advanced Polymer Technologies, and Performance Materials. The bulk of its revenue is generated by the Performance Chemicals segment which deals with the manufacture and sale of specialty chemicals that find their use in a range of processes such as asphalt paving, oil exploration and production, agrochemicals, adhesives, lubricants, and publication inks. The Performance Materials segment, on the other hand, focuses on automotive carbon products used in automobiles. The Advanced Polymer Technologies segment produces caprolactone and caprolactone-based specialty polymers. The company generates the majority of its revenue from North America.
62GF Score
Get the complete analysis for FRA:IGX
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:IGX has been successfully added to your 
